Form SC 13G/A AbbVie Inc. Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Abbvie (ABBV) Humira guidance removes overhang - Truist
February 9, 2023 1:39 PM ESTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $180.00 price target on Abbvie (NYSE: ABBV) as Humira guidance removes overhang.
The analyst commented, "Following ABBV's 4Q2022 earnings call, we are reiterating our Buy rating as 1) we believe that the guidance provided... More
